PEPTIDE GUARDIANResearch literacy for peptides

Compounds / Metabolic

AOD-9604

Also written as: AOD9604, AOD 9604, Tyr-hGH 177-191 (descriptive name: growth hormone residues 177-191 with an added tyrosine), AOD-9604 acetate (the acetate salt, a different chemical form), Anti-obesity drug 9604 (a name used on some websites, according to FDA)

AOD-9604 is a lab-made 16-amino-acid piece of human growth hormone that reduced fat gain in obese rodents, but in its largest human trial, of about 500 adults, it did not produce significant weight loss and it has never been approved as a medicine.

Where the evidence stands

  1. 1 of 4Animal and cell studies only
  2. 2 of 4Early human trials
  3. 3 of 4Late-stage human trials
  4. 4 of 4Approved medicine

The short version

  • AOD-9604 is a lab-made peptide: a 15-amino-acid piece from the tail end of human growth hormone with one extra amino acid (tyrosine) added at the front. It is not an FDA-approved drug.
  • In obese rats and mice, studies from Monash University in Australia reported less weight gain and more fat breakdown, without the blood-sugar effects of full growth hormone.
  • In people, the developer's largest trial (502 adults with obesity, 24 weeks) found weight loss compared with placebo was too small to be statistically significant. The company ended obesity development in February 2007.
  • The developer's trials, mostly by mouth, reported side effects at similar rates on AOD-9604 and placebo. The FDA said in 2024 the reports lacked detail and it could not rule out a link to serious events in five people, including cancers, in a 12-week trial.
  • A 2012 'GRAS' claim was a conditional self-affirmed determination by a panel the company hired. FDA's GRAS notice inventory has no entry for AOD-9604, and GRAS is not drug approval.
  • It is not on the list of substances US pharmacies may compound from. An FDA advisory committee voted 12 to 0 against adding it in December 2024, and it is not in the October 2026 HHS draft peptide policy.
  • It is banned in sport at all times: the WADA Prohibited List names it as a growth hormone fragment (class S2.2.3).

What it is

AOD-9604 is a peptide, a short chain of amino acids (the building blocks of proteins). It has 16 amino acids. Fifteen of them copy positions 177 to 191 at the very end of human growth hormone. The sixteenth, a tyrosine, was added at the front. Two of its amino acids (cysteines) are joined to each other, which closes the chain into a small ring. It is made in a laboratory by chemical synthesis.

More on what it is and where it came from

It is easy to confuse with two relatives. Human growth hormone itself is a protein of 191 amino acids that acts on growth hormone receptors throughout the body. 'HGH fragment 176-191' is the last 16 amino acids of growth hormone, which starts with phenylalanine at position 176. AOD-9604 starts with tyrosine instead, so the two differ by one amino acid and weigh almost the same (about 1815 versus 1799 g/mol on PubChem). The anti-doping rules list them as two separate examples. A cell study found that, unlike growth hormone, AOD-9604 did not attach to the growth hormone receptor and did not make cells multiply.

It was developed as a possible obesity pill by Metabolic Pharmaceuticals of Melbourne, Australia, and tested in six company-funded human trials, the last of which reported in 2007. The FDA wrote in 2024 that it is not part of any FDA-approved drug and that there is no official quality standard (pharmacopoeia monograph) for it. The FDA also noted that the plain peptide (free base) and its acetate salt are different substances, and that some sellers give a different CAS number or a structure that does not match the sequence.

In the 1990s, F.M. Ng and colleagues in the biochemistry department of Monash University in Australia reported that a synthetic copy of growth hormone positions 177 to 191 reduced fat-making in rat fat tissue and reduced weight gain in genetically obese mice. Metabolic Pharmaceuticals then developed AOD-9604, the same piece with a tyrosine added, as an obesity drug; the FDA says it was first developed and patented in the late 1990s. The company ran six trials, the last a 24-week phase 2b trial called the OPTIONS Study. On 21 February 2007 it told the Australian stock exchange that the results did not support the drug's commercial viability for obesity and that development for that use was terminated. In 2012 its parent company, Calzada, announced a conditional, self-affirmed 'GRAS' determination and said it would seek to license AOD-9604 as a food and supplement ingredient in the US.

How it is thought to work

Nobody knows exactly how it works. The FDA wrote in 2024 that its molecular targets and mechanisms 'remain unknown'. In obese mice and rats it appeared to reduce the making of new fat (lipogenesis), increase fat breakdown (lipolysis) and increase fat burning, measured by breathing gases and a blood marker of fat breakdown (glycerol).

More on how it works

In a cell test it did not bind to the growth hormone receptor, which is how full growth hormone works. In mice bred without the beta-3 adrenergic receptor (a switch on fat cells that triggers fat breakdown), two weeks of treatment no longer reduced weight, which suggests that pathway is involved somehow. Unlike growth hormone, it did not raise blood sugar or reduce insulin release in these rodent studies.

It breaks down fast. In company studies summarised by the FDA, its half-life was about 4 minutes in rat blood in a test tube and about 3 minutes in pigs after injection into a vein. The FDA found no study measuring how the human body absorbs or clears it by any route.

What is established in people

Six company-funded, placebo-controlled trials gave AOD-9604 to people, most by mouth, for up to 24 weeks; 893 people took part in total. None showed convincing weight loss. The largest, in 502 adults with obesity over 24 weeks, missed its main goal, and the 12-week trial in 300 adults reached significance only in a subgroup of women. Development for obesity stopped in 2007. The full trial results were never published in a journal, and there are no human studies of AOD-9604 injected under the skin, which is how it is now commonly sold.

What the studies found

11 studies, human trials first. Each links to the paper or registry record.

  1. Human trial2007

    Metabolic's obesity drug - Phase 2B clinical trial results (the OPTIONS Study, trial METAOD006)

    This is the largest trial.

    Full finding, who was studied, and limits

    Who: 536 adults with obesity enrolled (BMI 30 to 45, aged 18 to 65, about equal numbers of men and women) at 16 sites in Australia; 502 were randomly assigned to one of three AOD-9604 groups or placebo, about 125 per group, taken by mouth once daily for 24 weeks, double-blind, alongside a dietitian-supervised diet and exercise programme.

    This is the largest trial. The main goal, statistically significant weight loss versus placebo at 12 weeks for any group, was 'Not met'. The company said weight loss compared with placebo at 12 or 24 weeks 'was too low to reach statistical significance' and was less than 1 kg in all groups after allowing for the diet and exercise programme. The trial had been designed to detect a 1.8 kg difference. A pre-planned subgroup of 149 women who had lost little weight in the run-in showed some separation from placebo. The company concluded the trial results 'do not support the commercial viability' of the drug for obesity and terminated that development.

    Read with care: A company announcement, not a peer-reviewed paper, and the FDA found no journal publication. About 29% of randomised participants had left by week 24. The subgroup result was not the main test and should not be read as proof of benefit.

    Company announcement to the Australian Securities Exchange, 21 February 2007 (copy filed with the US Securities and Exchange Commission). Not published in a journal. · sec.gov

  2. Human trial2005

    The Effect of AOD9604 on Weight Loss in Obese Adults: Results of a Randomized, Double-Blind, Placebo-Controlled, Multicenter Study (trial METAOD005)

    The authors reported that every AOD-9604 group lost more weight than placebo, but the differences were small and the dose pattern was irregular.

    Full finding, who was studied, and limits

    Who: 300 otherwise healthy men and women with obesity, aged 30 to 65, randomly assigned to one of five AOD-9604 groups or placebo (50 per group) for 12 weeks by mouth, after a two-week run-in. There was no formal diet and exercise programme.

    The authors reported that every AOD-9604 group lost more weight than placebo, but the differences were small and the dose pattern was irregular. The company later said the best group fell short of statistical significance overall (p=0.1, where 0.05 was required) and reached significance only in women. Waist size fell more on AOD-9604. The FDA said the claimed weight reduction rested on small differences of unclear clinical meaning.

    Read with care: Published only as a meeting abstract; the FDA could not find a full paper with methods and results. A significant result in one subgroup (women) after missing the main target is weak evidence. Twelve weeks is short for an obesity drug.

    Meeting abstract in Obesity Research, as described in the FDA briefing document of 5 November 2024; also summarised by the company in its 2007 stock-exchange announcement and in Stier et al. 2013 · fda.gov

  3. Human trial2004

    AOD-9604 Metabolic.

    In the infusion trial a blood marker of fat breakdown rose within hours, and the average weight change of about 0.6 kg over three weeks was not different from placebo.

    Full finding, who was studied, and limits

    Who: Three small early placebo-controlled trials in men with obesity: 23 men given infusions into a vein, 16 to 17 men given single doses by mouth, and 36 men treated by mouth for one week.

    In the infusion trial a blood marker of fat breakdown rose within hours, and the average weight change of about 0.6 kg over three weeks was not different from placebo. In the single-dose oral trial there was no statistically significant weight loss compared with placebo. In the one-week trial the article reported 1 kg average loss in one group versus 0.6 kg on placebo, with other groups doing worse. The FDA summarised that these studies did not show statistically significant weight loss.

    Read with care: Tiny, very short trials described only briefly. The FDA noted the article's sources were company press releases that are no longer available.

    Current Opinion in Investigational Drugs (a drug-profile article); trial details as summarised by the FDA briefing document of 5 November 2024 · fda.gov

  4. Review2024

    FDA Evaluation of AOD-9604-Related Bulk Drug Substances (AOD-9604 (free base) and AOD-9604 acetate) for Inclusion on the 503A Bulk Drug Substances List

    The FDA concluded there was 'a lack of evidence to support the effectiveness' of AOD-9604 for obesity by any route, that 'In most of the studies we identified, AOD-9604 failed to show benefit', and that its use in compounding 'may raise safety concerns'.

    Full finding, who was studied, and limits

    Who: FDA chemists, toxicologists and clinicians reviewed the chemistry, animal studies, human trials and FDA side-effect databases for AOD-9604 for obesity.

    The FDA concluded there was 'a lack of evidence to support the effectiveness' of AOD-9604 for obesity by any route, that 'In most of the studies we identified, AOD-9604 failed to show benefit', and that its use in compounding 'may raise safety concerns'. It found no human data at all for injection under the skin or application to the skin, no human absorption studies, and called the substance not well characterised chemically. It proposed not adding AOD-9604 or its acetate to the 503A list.

    Read with care: A staff review for an advisory meeting, assessing obesity only. It relies on the same thin company summaries as everyone else, because full trial reports were never published.

    FDA briefing document for the Pharmacy Compounding Advisory Committee meeting of 4 December 2024 (memo dated 5 November 2024) · fda.gov

  5. Review2013

    Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans

    It reports safety only, not weight loss.

    Full finding, who was studied, and limits

    Who: A summary of safety data from all six company trials, 893 participants in total: two vein-infusion trials (15 healthy men; 23 men with obesity) and four by mouth (17 and 36 men with obesity; 300 and 502 adults with obesity). Written by people paid by or holding shares in the developer, which funded all six trials.

    It reports safety only, not weight loss. Blood IGF-1 (a growth-hormone-driven hormone) did not change compared with placebo in any trial, and glucose tolerance did not worsen. No antibodies against the peptide were found in those tested. In the 24-week trial 78.7% of participants had at least one side effect, from 75.6% in one AOD-9604 group to 83.2% on placebo, and 3.6% had a serious adverse event, spread similarly across groups. The authors called the profile 'indistinguishable from placebo'.

    Read with care: Company-written, no efficacy results, and limited detail. Kenley held a 6.9% interest in the parent company; Vos was a consultant and former medical director; Stier's employer consulted for the company. The FDA said these summaries lacked the detail needed to judge safety. None of the trials gave AOD-9604 by injection under the skin.

    Journal of Endocrinology and Metabolism · jofem.org

  6. Animal study2015

    Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model.

    AOD-9604 alone did better than salt water on cartilage scores, and AOD-9604 combined with hyaluronic acid gave the best cartilage scores and the shortest period of limping.

    Full finding, who was studied, and limits

    Who: 32 rabbits with chemically induced knee arthritis, given weekly injections into the knee of AOD-9604, hyaluronic acid (a standard joint lubricant injection), both, or salt water.

    AOD-9604 alone did better than salt water on cartilage scores, and AOD-9604 combined with hyaluronic acid gave the best cartilage scores and the shortest period of limping.

    Read with care: Rabbits, one small study from one group. The FDA did not evaluate AOD-9604 for osteoarthritis because it found no human studies in that condition. It is often marketed for joints on the strength of animal work like this.

    Annals of Clinical and Laboratory Science · pubmed.ncbi.nlm.nih.gov

  7. Animal study2014

    Safety and Metabolism of AOD9604, a Novel Nutraceutical Ingredient for Improved Metabolic Health

    The authors concluded there were no genetic-damage or toxicity concerns.

    Full finding, who was studied, and limits

    Who: Company safety studies: genetic-damage tests in bacteria, hamster cells and rat bone marrow; 6-month studies in rats and a 9-month study in monkeys with the peptide given by mouth; absorption studies in pigs and rats. Co-written by Metabolic Pharmaceuticals' chief executive.

    The authors concluded there were no genetic-damage or toxicity concerns. Reading the same paper in 2024, the FDA disagreed on several points: dose-related changes in a bone marker (osteocalcin) in rats that it called a possible bone-health safety signal; small fat-like spaces in liver cells of all female monkeys in the highest group, which can signal liver injury; and positive results in some genetic-damage tests that the authors had dismissed. The FDA said the paper gave no data tables.

    Read with care: Written by the developer to support food-ingredient use. No animal cancer studies and no reproductive studies exist, according to the FDA. No studies used injection under the skin, the way AOD-9604 is now commonly sold.

    Journal of Endocrinology and Metabolism · jofem.org

  8. Animal study2001

    Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment.

    Both growth hormone and AOD-9604 reduced weight gain in obese mice, with more fat burning and higher blood glycerol (a marker of fat breakdown).

    Full finding, who was studied, and limits

    Who: Obese (ob/ob) and lean mice treated for 14 days with growth hormone, AOD-9604 or salt water through a small pump under the skin, plus a cell test with cells carrying the growth hormone receptor. Heffernan, Ng and colleagues. Group sizes are not given in the abstract.

    Both growth hormone and AOD-9604 reduced weight gain in obese mice, with more fat burning and higher blood glycerol (a marker of fat breakdown). Growth hormone raised blood sugar and cut insulin release; AOD-9604 did neither. In the cell test AOD-9604 did not compete for the growth hormone receptor and did not make cells multiply. The FDA's reading of this and the companion paper is that treated obese mice gained about 5 to 10% less body weight than untreated ones.

    Read with care: Mice, two weeks. A modest effect on weight gain in mice bred to be obese does not predict weight loss in people, and the later human trials did not show it.

    International Journal of Obesity and Related Metabolic Disorders · pubmed.ncbi.nlm.nih.gov

  9. Animal study2001

    The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice.

    In obese mice both treatments reduced body weight and body fat and raised activity of the beta-3 receptor gene to the level of lean mice.

    Full finding, who was studied, and limits

    Who: Obese mice and mice bred without the beta-3 adrenergic receptor, treated for 14 days with growth hormone or AOD-9604. Group sizes are not given in the abstract.

    In obese mice both treatments reduced body weight and body fat and raised activity of the beta-3 receptor gene to the level of lean mice. In mice lacking that receptor, two weeks of treatment did not reduce weight or increase fat breakdown, although a single treatment still raised energy use and fat burning.

    Read with care: Mice. It points to a pathway but does not identify what the peptide acts on; the FDA says the target is still unknown.

    Endocrinology · pubmed.ncbi.nlm.nih.gov

  10. Animal study2000

    Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone.

    Weight gain was cut by more than half compared with controls, and fat tissue showed more fat-breakdown activity.

    Full finding, who was studied, and limits

    Who: Obese Zucker rats given AOD-9604 by mouth daily for 19 days, compared with untreated obese rats. Group sizes are not given in the abstract.

    Weight gain was cut by more than half compared with controls, and fat tissue showed more fat-breakdown activity. Tests of insulin action (clamp studies) showed no harm to insulin sensitivity, unlike long-term full growth hormone. The authors suggested it could become an obesity treatment taken by mouth.

    Read with care: Rats bred to be obese, short treatment, group sizes not stated in the abstract. The FDA cautioned that these rodent studies did not test more than one dose level and did not correct their statistics for multiple comparisons.

    Hormone Research · pubmed.ncbi.nlm.nih.gov

  11. Animal study1994

    Reduction of cumulative body weight gain and adipose tissue mass in obese mice: response to chronic treatment with synthetic hGH 177-191 peptide.

    Treated obese mice gained less weight over time and had less fat tissue, and fat-making in their fat tissue was significantly reduced.

    Full finding, who was studied, and limits

    Who: Genetically obese (ob/ob) mice given long-term treatment with synthetic growth hormone residues 177-191, the parent piece of AOD-9604 without the added tyrosine. Monash University. The abstract does not give the number of mice.

    Treated obese mice gained less weight over time and had less fat tissue, and fat-making in their fat tissue was significantly reduced. The authors suggested the peptide might be useful in human obesity.

    Read with care: Mice bred to be obese, not people. The abstract gives no figures for the size of the effect. This is the 15-amino-acid parent peptide, not AOD-9604 itself.

    Biochemistry and Molecular Biology International · pubmed.ncbi.nlm.nih.gov

Safety findings

  • In the developer's summary of six trials, side effects were reported at similar rates on AOD-9604 and placebo. In the 24-week trial 78.7% of all participants had at least one side effect (83.2% on placebo) and 3.6% had a serious adverse event, spread similarly across groups. The most common complaints there were colds, headache, back pain and diarrhoea. IGF-1 and glucose tolerance did not change and no antibodies were found in those tested. The authors were company employees or consultants. Source: jofem.org
  • In the 12-week trial, five people had serious adverse events, all in AOD-9604 groups as listed by the FDA: basal cell carcinoma, squamous cell carcinoma (both skin cancers), a lipoma (a fatty lump), breast cancer and malignant melanoma. The investigator judged none related to the drug. The FDA wrote that it had 'concerns about the reports of various cancers' and that the information was insufficient to say whether they were unrelated. Source: fda.gov
  • Other events the trial reports linked as possibly related to AOD-9604, as summarised by the FDA: a severe feeling of chest tightness and mild to moderate euphoria (five people on AOD-9604, none on placebo) in a vein-infusion trial, and serious diarrhoea in a single-dose oral trial. In a one-week oral trial the highest-dose group had more headaches, diarrhoea and wind. Source: fda.gov
  • FDA side-effect databases: a search of the FDA Adverse Event Reporting System to 7 January 2024 found no reports, and the food and supplement reporting system (CAERS) found none from 2004 to April 2024. The FDA added that no reports does not mean the substance is safe. Its compounding page, current as of 22 April 2026, says it 'has also identified serious adverse events that may be associated with AOD-9604, though causality is not clear'; the page does not say which events. Source: fda.gov
2 more safety findings
  • Animal safety signals, as read by the FDA from the company's toxicology paper: changes in a bone marker (osteocalcin) in rats over six months that may point to effects on bone; liver-cell changes in female monkeys after nine months that can indicate liver injury; and equivocal results in three genetic-damage tests. No animal cancer or reproductive studies were found. Source: fda.gov
  • Unknowns: no human study has measured how AOD-9604 is absorbed or cleared, no human study has given it by injection under the skin or on the skin, and the longest human exposure was 24 weeks. The FDA said injected peptides of this length may provoke an immune response, made more likely by impurities and clumping, and that there is no information to assess that risk for injection under the skin. This is a risk the FDA could not rule out, not an effect seen in patients. Source: fda.gov

Rules and status

Not an FDA-approved drug and not part of any FDA-approved drug (FDA, November 2024). Not on the list of bulk substances US pharmacies may compound from (the 503A bulks list). It is not one of the six peptides named in the HHS draft enforcement-discretion policy of 30 October 2026.

The full history, with dates

Approval: the FDA's 2024 review states AOD-9604 is not a component of an FDA-approved drug and found no listing in the European Medicines Agency or major pharmacopoeias. ClinicalTrials.gov listed no studies of it when searched on 18 November 2026. Compounding: AOD-9604 was nominated for the 503A bulks list (by Wells Pharmacy and the International Peptide Society, according to FDA) and placed in Category 2 of FDA's interim policy, the group that 'may present significant safety risks'. The nominations were later withdrawn, and it now appears in the 'Bulk drug substances nominated but withdrawn' table on FDA's page (content current as of 22 April 2026), which gives this reason: 'Compounded drugs containing AOD-9604 may pose significant risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and API characterization. FDA has identified no, or only limited, safety-related information. Therefore, the agency lacks sufficient information to know whether the drug would cause harm when administered to humans. FDA has also identified serious adverse events that may be associated with AOD-9604, though causality is not clear.' Despite the withdrawals, FDA evaluated AOD-9604 and its acetate on its own initiative and proposed not adding either to the list (briefing memo dated 5 November 2024). At the Pharmacy Compounding Advisory Committee meeting of 4 December 2024 the committee voted 12 to 0, with no abstentions, against placing them on the list (final minutes approved 21 February 2025). It does not appear in any category of FDA's nominated-substances list updated 14 May 2026, and it was not on the agenda of the 23 and 24 July 2026 advisory committee meeting. 2026 changes: on 30 October 2026 HHS published a draft, non-binding enforcement-discretion policy (91 FR 68526) for 503A compounding of certain peptides; its Appendix A names six peptides (BPC-157, epitalon, KPV, MOTS-c, semax, TB-500) and AOD-9604 is not among them, so that policy does not cover it. A web search on 18 November 2026 found no Federal Register proposed or final rule on AOD-9604. Food use: see the GRAS claim below; FDA's GRAS notice inventory has no entry for AOD-9604.

Source: fda.gov (source dated 2026-04-22)

In sport: Prohibited at all times, in and out of competition, as a non-Specified Substance in class S2 (Peptide hormones, growth factors, related substances and mimetics). Section S2.2.3, 'Growth hormone (GH), its analogues and fragments', lists 'growth hormone fragments, e.g. AOD-9604 and hGH 176-191' in both the 2026 List (in force from 1 January 2026) and the 2027 List (published 21 September 2026, in force from 1 January 2027). WADA

Claims and what the evidence supports

What people sayWhat the evidence supports
AOD-9604 is FDA approved.It is not. The FDA wrote in 2024 that AOD-9604 is not a component of any FDA-approved drug, concluded there was a lack of evidence that it works for obesity, and proposed not allowing pharmacies to compound it. Its advisory committee agreed 12 to 0. Source: fda.gov
AOD-9604 has GRAS status from the FDA.In June 2012 the company announced a 'conditional', 'self-affirmed' GRAS determination by an expert panel it had contracted (GRAS Associates), for use as a food ingredient, conditional on publishing its safety studies. GRAS ('generally recognised as safe') is a food-ingredient concept; a self-affirmed determination is the company's own conclusion, not an FDA decision. Searches of FDA's GRAS notice inventory for 'AOD-9604', 'AOD9604', 'hexadecapeptide' and 'Calzada' on 18 November 2026 returned 0 records, so no GRAS notice for it appears in FDA's inventory, which lists notices filed since 1998. GRAS says nothing about injected products or medical use. Source: hfpappexternal.fda.gov
It is TGA approved in Australia.I found no primary record of approval as a medicine. The developer ended obesity development after its phase 2b trial in 2007, and its parent company described AOD-9604 in 2012 as an ingredient in a cosmetic cream and a planned US food ingredient, not an approved medicine. The FDA's 2024 review reports that Australia's medicines scheduling committee added AOD-9604 to the Poisons Standard as a performance and image enhancing drug, which makes possession without authority, such as a prescription, illegal. The Therapeutic Goods Administration website did not respond to my requests, so I could not check its register directly. Source: fda.gov
Clinical trials proved it melts fat.The opposite. In the largest trial, 502 adults over 24 weeks, weight loss compared with placebo was less than 1 kg and not statistically significant, and the company terminated obesity development. The FDA wrote that in most studies 'AOD-9604 failed to show benefit'. The fat-burning results come from obese rats and mice. Source: sec.gov
It is the same thing as HGH fragment 176-191.It is not. AOD-9604 is growth hormone positions 177-191 with a tyrosine added at the front; fragment 176-191 has phenylalanine there instead. WADA lists them as separate examples, and PubChem gives them different formulas and weights (1815.1 versus 1799.1 g/mol). The human trials used AOD-9604 only. Source: wada-ama.org
It gives the fat-loss effect of growth hormone without the side effects.In obese mice it did not raise blood sugar, unlike growth hormone, and in human trials IGF-1 and glucose tolerance did not change. But it also did not produce meaningful weight loss in people. Human side-effect rates looked similar to placebo in company summaries, while the FDA flagged cancers in one trial and animal signals for bone and liver that have not been resolved. Source: pubmed.ncbi.nlm.nih.gov
It repairs cartilage and helps arthritis.One study in 32 rabbits with induced knee arthritis reported better cartilage scores after injection into the knee. There are no human studies; the FDA found none and did not evaluate this use. Source: pubmed.ncbi.nlm.nih.gov
It has been safety-tested in about 900 people.893 people took part in six company trials, almost all taking it by mouth or by vein infusion for 24 weeks or less. The safety reports were written by company-linked authors and, according to the FDA, lack detail. No one has studied it injected under the skin, and no human absorption studies exist. Source: jofem.org

What a genuine lab report should show

  • Identity by mass spectrometry: the measured mass should match about 1815.1 g/mol for the free base (formula C78H123N23O23S2). This separates it from HGH fragment 176-191, which weighs about 1799.1 g/mol (C78H123N23O22S2), a difference of roughly 16 g/mol (one oxygen atom). A report that does not resolve this difference cannot tell the two apart.
  • The sequence should be confirmed as Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe, with the two cysteines (positions 7 and 14) joined in a disulfide bond. The FDA said the most common impurities are the broken (reduced) disulfide form, two-molecule dimers and clumps formed through disulfide bridges.
  • The report should state which form was tested: free base (CAS 221231-10-3) or acetate salt. The FDA found certificates where the named form, CAS number, formula and weight did not match each other, and noted some suppliers use a different CAS number (386264-39-7).
  • Purity by HPLC with peptide-related impurities reported, not only a single 'purity' percentage. The FDA criticised certificates that gave no impurity, aggregate or microbial results.
  • For any product meant for injection: bacterial endotoxin and sterility or bioburden results. The FDA named these as critical and said they were missing from the certificates it reviewed.
  • A lot-specific certificate tied to the batch number on the vial, naming the testing laboratory and dated, plus peptide content (how much peptide is actually present), which is a different measurement from purity.

How to read a lab report

What is not known

  • Status in Australia: the FDA's 2024 review says Australia scheduled AOD-9604 as a controlled performance and image enhancing drug, but the TGA website timed out on every request, so I could not open the scheduling decision or search the Australian Register of Therapeutic Goods. Vendor sites make conflicting claims about past register entries; none were used. An editor should check the TGA register and Poisons Standard by hand.
  • Full trial results: neither the 12-week trial (300 people) nor the 24-week OPTIONS Study (502 randomised) was published in a journal with full methods and results. Everything known about effectiveness comes from a meeting abstract, company announcements and a company-written safety summary.
  • Were the five serious events in the 12-week trial, including cancers, related to AOD-9604? The investigator said no; the FDA said the information was insufficient to decide.
  • Which 'serious adverse events' does FDA's April 2026 compounding page mean? Its 2024 database searches found no reports, so the page may refer to the trial events, but it does not say.
  • Numbers differ slightly between sources: 534 (Stier et al.) versus 536 (company announcement and FDA) enrolled in the OPTIONS Study; 16 versus 17 men in the single-dose oral trial; the company said 925 people across six trials in 2012, while the 2013 safety paper says 893.
  • Could AOD-9604 lawfully be sold in US foods or supplements? The 2012 GRAS determination was self-affirmed and conditional, and no GRAS notice appears in FDA's inventory. I did not find an FDA statement on its food or supplement status and did not research the separate legal rules on adding drug-tested substances to foods.
  • PubChem's record (CID 71300630) lists the synonyms 'Tyr-somatostatin (177-191)' and 'Somatostatin (177-191), tyrosyl-'. These appear to confuse somatostatin with somatotropin (growth hormone); the structure and formula match AOD-9604.
  • The FDA briefing document describes the added tyrosine as N-terminal in most places but once (page 24) as C-terminal. Its chemical name, the PubChem name and the growth hormone sequence all place it at the N-terminus (the front).

Sources

All 27 sources
  1. PubChem: AOD-9604, CID 71300630 (formula, weight, CAS, synonyms). pubchem.ncbi.nlm.nih.gov
  2. PubChem: Somatotropin (176-191), CID 16131230 (for comparison). pubchem.ncbi.nlm.nih.gov
  3. UniProt P01241: human growth hormone sequence (mature chain positions 27-217). uniprot.org
  4. Wu and Ng 1993, hGH 177-191 reduces fat-making in rats (Monash). pubmed.ncbi.nlm.nih.gov
  5. Natera, Jiang and Ng 1994, hGH 177-191 in obese mice (Monash). pubmed.ncbi.nlm.nih.gov
  6. Ng et al. 2000, AOD9401 (hGH 177-191) in obese Zucker rats. pubmed.ncbi.nlm.nih.gov
  7. Ng et al. 2000, AOD9604 by mouth in obese Zucker rats. pubmed.ncbi.nlm.nih.gov
  8. Heffernan et al. 2001, obese mice and growth hormone receptor test. pubmed.ncbi.nlm.nih.gov
  9. Heffernan et al. 2001, beta-3 receptor knockout mice. pubmed.ncbi.nlm.nih.gov
  10. Wilding 2004, AOD-9604 drug profile. pubmed.ncbi.nlm.nih.gov
  11. Stier, Vos and Kenley 2013, safety of AOD9604 in six human trials. jofem.org
  12. More and Kenley 2014, company toxicology and metabolism studies. jofem.org
  13. Kwon and Park 2015, rabbit knee osteoarthritis. pubmed.ncbi.nlm.nih.gov
  14. Cox et al. 2015, detection and metabolism of AOD9604 for doping control. pubmed.ncbi.nlm.nih.gov
  15. Metabolic Pharmaceuticals ASX announcement, 21 February 2007: Phase 2B results, obesity programme terminated (company announcement; SEC copy). sec.gov
  16. Calzada ASX announcement, 25 June 2012: 'AOD9604 Receives GRAS Status' (company announcement). aspecthuntley.com.au
  17. FDA GRAS Notice Inventory search for AOD-9604: 0 records (page updated 2 November 2026). hfpappexternal.fda.gov
  18. FDA briefing document on AOD-9604 for the 4 December 2024 Pharmacy Compounding Advisory Committee. fda.gov
  19. FDA final summary minutes, Pharmacy Compounding Advisory Committee, 4 December 2024 (AOD-9604 vote 0 yes, 12 no). fda.gov
  20. FDA: bulk drug substances that may present significant safety risks (content current as of 22 April 2026). fda.gov
  21. FDA: 503A nominated substances by category, updated 14 May 2026 (AOD-9604 not listed). fda.gov
  22. FDA: 23-24 July 2026 Pharmacy Compounding Advisory Committee meeting page (AOD-9604 not on agenda). fda.gov
  23. Federal Register, 30 October 2026, 91 FR 68526: HHS peptide enforcement-discretion policy notice. govinfo.gov
  24. HHS Enforcement Discretion Policy with Appendix A (six peptides; AOD-9604 not included) and Appendix B. hhs.gov
  25. WADA 2026 Prohibited List (S2.2.3 names AOD-9604). wada-ama.org
  26. WADA news, 21 September 2026: 2027 Prohibited List published (S2.2.3 names AOD-9604). wada-ama.org
  27. ClinicalTrials.gov search for AOD9604 / AOD-9604: no studies (18 November 2026). clinicaltrials.gov

Sources last checked 2026-11-18.

This page summarises published research and public records for education. It is not medical advice and it is not a guide to using any compound. If something here is wrong or out of date, tell us and we will correct it.

Get the Guardian Field Guide

Every compound on this site in one guide: what it is, what studies found, and where it stands with regulators. Sent to your email, with a note when a compound page or its legal status changes.

Sign-up link not connected yet.